{"doi":"10.21037/apc-2022-3","title":"Battling pancreatic cancer: the role of Chinese surgeons","abstract":"Pancreatic cancer is becoming an increasingly common cause of cancer mortality and a growing global burden.The survival rate of pancreatic cancer has always been dismal, but it is improving with state-of-the-art multidisciplinary treatment strategies.The most recent data from the Surveillance, Epidemiology, and End Results (SEER) program showed that the 5-year survival rate of pancreatic cancer has reached 11.5% (1).While this looks promising, it is still far from satisfactory and there is room for improvement.International collaboration is the key to maximizing creativity and innovation in terms of the development of diagnosis and treatment strategies that can improve the survival rate of this lethal malignancy.The prognosis of pancreatic cancer patients in China has been improving due to the continuous efforts of Chinese physicians (2), who have emerged as key innovators in the development of novel treatment strategies for pancreatic cancer.Under the leadership of Prof. Yupei Zhao, the Honorary President of Peking Union Medical College Hospital, Chinese pancreatic surgeons have made great efforts and contributions to the global innovation network in pancreatic cancer.I have visited China many times, and have attended the International HBP Forum, a large-scale, high-profile meeting that focuses on pancreatic cancer in China.During the International HBP Forum, I met and familiarized myself with many talented Chinese pancreatic surgeons, including the organizer of the forum, Prof. Tingbo Liang.In my view, Prof. Liang has always been a pioneer and innovator in the field of pancreatic cancer in China.","journal":"Annals of Pancreatic Cancer","year":2022,"id":312734,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9538,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":277000,"name":"Lei Zheng","orcid":"0000-0003-4163-2541","position":0,"is_corresponding":true}],"reference_count":2,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:33:40.460845Z","pmid":"37223104","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}